山东15-40岁人群乙肝疫苗2剂与3剂20年抗体持久性比较
该研究对山东15-40岁人群基础免疫乙肝疫苗后随访20年,比较2剂(0-6)与3剂(0-1-6)方案的抗体持久性。结果显示3剂方案抗-HBs阳性率和GMC均高于2剂方案,且两者随随访时间下降,慢性病史与GMC相关。
要点
- 20年后3剂方案抗-HBs阳性率69.68%,2剂方案51.01%。
- 3剂方案GMC在各时点均高于2剂方案。
- 慢性病史与较低抗-HBs GMC相关。
核心结论
- 与3剂HepB相比,2剂HepB接种者抗-HBs阳性率和GMC均较低。
- 抗-HBs阳性率与免疫程序和随访时间有关。
- 抗-HBs GMC与免疫程序、随访时间和慢性病史有关。
研究设计与样本
- 随机分配至「0-1-6」组428名和「0-6」组422名,使用10 μg HepB基础免疫。
- 629名完成全程免疫及免疫后1个月采血检测,最终304名完成1个月、12年和20年随访。
主要发现
- 2003、2015、2023年「0-1-6」组抗-HBs阳性率分别为94.19%(95%CI:89.26%-97.31%)、74.19%(95%CI:66.56%-80.88%)、69.68%(95%CI:61.79%-76.79%)。
- 2003、2015、2023年「0-6」组抗-HBs阳性率分别为87.25%(95%CI:80.80%-92.14%)、55.03%(95%CI:46.68%-63.18%)、51.01%(95%CI:42.70%-59.28%)。
- 2003、2015、2023年「0-1-6」组抗-HBs GMC分别为268(95%CI:200-359)mIU/ml、34(95%CI:26-46)mIU/ml、37(95%CI:27-51)mIU/ml。
- 2003、2015、2023年「0-6」组抗-HBs GMC分别为121(95%CI:87-168)mIU/ml、13(95%CI:9-18)mIU/ml、15(95%CI:11-20)mIU/ml。
- 多因素分析:「0-6」组抗-HBs阳性率OR=0.45(95%CI:0.30-0.68,P<0.001),2015年OR=0.17(95%CI:0.12-0.25,P<0.001),2023年OR=0.14(95%CI:0.10-0.20,P<0.001)。
关键数值与推荐
- 抗-HBs阳性率「0-1-6」组与「0-6」组差异有统计学意义(均P<0.001)。
- 与2003年相比,2015年和2023年抗-HBs阳性率和GMC均较低(均P<0.001)。
- 随访时间与免疫程序对抗-HBs阳性率和GMC不存在交互效应(均P>0.05)。
- 「0-6」组GMC β=-0.83(95%CI:-1.19--0.47,P<0.001),2015年β=-2.15(95%CI:-2.37--1.93,P<0.001),2023年β=-2.04(95%CI:-2.27--1.80,P<0.001),有慢性病史β=0.55(95%CI:0.02-1.08,P=0.043)。
临床怎么用
- 3剂HepB方案在20年随访中抗体持久性优于2剂方案,支持现行3剂程序。
- 对完成2剂方案者,可关注长期抗体下降风险。
- 慢性病史者抗-HBs GMC较低,随访时可考虑重点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the antibody persistence and influencing factors of the simplified two-dose and standard three-dose hepatitis B vaccine (HepB) among people aged 15-40 years after 20 years of primary immunization. Methods: In November 2003, a total of 1 994 healthy people aged 15-40 were randomly selected from 20 villages in Jiyang County, Jinan City, Shandong Province. Venous blood samples were collected from 3-5 ml of people who tested negative for hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs), and anti-hepatitis B core antibody (anti-HBc). A total of 850 people were included in the study. The study randomly assigned 428 people to the "0-1-6" immunization program group and 422 people to the "0-6" immunization program group, and administered primary immunization to people using 10 μg HepB according to the corresponding program. 629 people completed full immunization and underwent blood sampling and anti-HBs testing one month after immunization. Blood samples were collected at 1 month, 12 years (2015), and 20 years (2023) after primary immunization, and solid-phase radioimmunoassay (SPRIA) or chemiluminescence particle immunoassay (CMIA) were used to detect anti-HBs, HBsAg, and anti-HBc. Simultaneously, a questionnaire survey was conducted, and information on birth date, gender, vaccination time, HepB immunization history, smoking history, alcohol consumption history, chronic disease history, and family members' hepatitis B infection history were collected during the baseline survey and follow-up survey. The generalized estimation equation (GEE) was used to analyze the main effects, interaction effects, and influencing factors of anti-HBs seropositive rates and geometric mean concentration (GMC). Results: A total of 304 people were followed up at 1 month, 12 years (2015), and 20 years (2023) after primary immunization, with 50.99% (155 people) in the "0-1-6" immunization program group. In 2003, 2015, and 2023, the seropositive rates of anti-HBs in the "0-1-6" immunization program group were 94.19% (95%CI: 89.26%-97.31%), 74.19% (95%CI: 66.56%-80.88%), and 69.68% (95%CI: 61.79%-76.79%), respectively. The seropositive rates of anti-HBs in the "0-6" immunization program group were 87.25% (95%CI: 80.80%-92.14%), 55.03% (95%CI: 46.68%-63.18%), and 51.01% (95%CI: 42.70%-59.28%), respectively. In 2003, 2015, and 2023, the anti-HBs GMC of the "0-1-6" immunization program group were 268 (95%CI: 200-359) mIU/ml, 34 (95%CI: 26-46) mIU/ml, and 37 mIU/ml (95%CI: 27-51), respectively. The anti-HBs GMC of the "0-6" immunization program group were 121 (95%CI: 87-168) mIU/ml, 13 (95%CI: 9-18) mIU/ml, and 15 (95%CI: 11-20) mIU/ml, respectively. The main effects analysis of GEE showed that there were statistically significant differences in the anti-HBs seropositive rates and GMC between the "0-1-6" immunization program group and the "0-6" immunization program group (both P<0.001). Compared with 2003, the anti-HBs seropositive rate and GMC were lower in 2015 and 2023 (both P<0.001). There was no interaction effect between the seropositive rate of anti-HBs and the follow-up time of anti-HBs GMC and the immunization program (both P>0.05). The multivariate analysis of GEE showed that compared with the "0-1-6" immunization program group and the 2003 baseline, the "0-6" immunization program group (OR=0.45, 95%CI: 0.30-0.68, P<0.001) had lower anti-HBs seropositive rates in 2015 and 2023 (OR=0.17, 95%CI: 0.12-0.25, P<0.001; OR=0.14, 95%CI: 0.10-0.20, P<0.001). Compared with the "0-1-6" immunization program group, baseline in 2003, and without chronic disease history, people in the "0-6" immunization program group (β=-0.83, 95%CI:-1.19--0.47, P<0.001) had lower anti-HBs GMC in 2015 and 2023 (β=-2.15, 95%CI:-2.37--1.93, P<0.001; β=-2.04, 95%CI:-2.27--1.80, P<0.001), and those with chronic disease history (β=0.55, 95%CI: 0.02-1.08, P=0.043). Conclusion: Compared with those receiving three-dose HepB, people receiving two-dose HepB have lower anti-HBs seropositive rates and GMC. Seropositive rates are associated with immunization program and follow-up duration, while the anti-HBs GMCs are associated with immunization program, follow-up duration, and chronic disease history. 目的: 探讨15~40岁人群基础免疫乙型肝炎疫苗(HepB)简化2剂次和现行3剂次20年后的抗体持久性及其影响因素。 方法: 于2003年11月,在山东省济南市济阳区,采用单纯随机抽样方法抽取20个村庄的15~40岁健康人群共1 994名,采集静脉血3~5 ml,HBsAg、抗-HBs和抗-HBc检测均阴性者,共计850名研究对象纳入研究。将这些研究对象随机分配至“0-1-6”免疫程序组(428名)和“0-6”免疫程序组(422名),按照对应程序使用10 μg HepB对参与者进行基础免疫;629名完成全程免疫及免疫后一个月的采血和抗-HBs检测。分别于基础免疫后1个月、12年(2015年)和20年(2023年)采集血标本,采用固相放射免疫法或化学发光微粒子免疫分析法检测抗-HBs、HBsAg和抗-HBc;同时进行问卷调查,于基线调查和随访调查时分别收集出生日期、性别、接种时间、HepB免疫史、吸烟史、饮酒史、慢性病史、家庭成员乙肝感染史信息。采用广义估计方程分析抗-HBs阳性和抗-HBs 几何均值(GMC)的主效应、交互效应及其影响因素。 结果: 基础免疫后1月、12年(2015年)和20年(2023年)共304名研究对象接受了随访,“0-1-6”免疫程序组对象占50.99%(155名)。2003、2015和2023年,“0-1-6”免疫程序组的抗-HBs阳性率分别为94.19 %(95%CI:89.26%~97.31%)、74.19%(95%CI:66.56%~80.88%)和69.68%(95%CI:61.79%~76.79%);“0-6”免疫程序组的抗-HBs阳性率分别为87.25%(95%CI:80.80%~92.14%)、55.03%(95%CI:46.68%~63.18%)和51.01%(95%CI:42.70%~59.28%)。2003、2015和2023年,“0-1-6”免疫程序组的抗-HBs GMC分别为268(95%CI:200~359)mIU/ml、34(95%CI:26~46)mIU/ml和37 mIU/ml(95%CI:27~51);“0-6”免疫程序组的抗-HBs GMC分别为121(95%CI:87~168)mIU/ml、13(95%CI:9~18)mIU/ml和15(95%CI:11~20)mIU/ml。广义估计方程主效应分析结果显示,“0-1-6”程序组与“0-6”程序组的抗-HBs阳性率、抗-HBs GMC差异均有统计学差异(均P<0.001);与2003年相比,2015年和2023年,抗-HBs 阳性率和GMC均较低(均P<0.001)。抗-HBs阳性率和抗-HBs GMC的随访时间与免疫程序不存在交互效应(均P>0.05)。广义估计方程多因素分析结果显示,与“0-1-6”程序、2003年基线相比,“0-6”程序组(OR=0.45,95%CI:0.30~0.68,P<0.001)、2015年和2023年(OR=0.17,95%CI:0.12~0.25,P<0.001;OR=0.14,95%CI:0.10~0.20,P<0.001)的抗-HBs 阳性率更低;与“0-1-6”程序、2003年基线、无慢性病史相比,“0-6”程序组(β=-0.83,95%CI:-1.19~-0.47,P<0.001)、2015年和2023年(β=-2.15,95%CI:-2.37~-1.93,P<0.001;β=-2.04,95%CI:-2.27~-1.80,P<0.001)、有慢性病史(β=0.55,95%CI:0.02~1.08,P=0.043)的参与者抗-HBs GMC更低。 结论: 与接种3剂次HepB疫苗者相比,接种2剂次者的抗体阳性率和GMC均较低;抗体阳性率与免疫程序和随访时间有关,抗体GMC与免疫程序、随访时间和慢性病史有关。.
引用
- Lyu JJ, Yan BY, Feng Y, et al. [Comparison of antibody persistence after two-dose and three-dose hepatitis B vaccines for 20 years among people aged 15-40 years in Shandong Province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42595536. doi:10.3760/cma.j.cn112150-20250819-00805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。